Modulation of lymphocyte function in vivo via inhibition of calcineurin or purine synthesis in patients with atopic dermatitis

J Invest Dermatol. 2012 Oct;132(10):2476-2479. doi: 10.1038/jid.2012.150. Epub 2012 May 24.

Affiliations

¹ Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: e.f.knol@umcutrecht.nl.
² Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
³ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

PMID: 22622424
DOI: 10.1038/jid.2012.150

No abstract available

Publication types

Controlled Clinical Trial
Letter

MeSH terms

B-Lymphocytes / drug effects
B-Lymphocytes / physiology*
Calcineurin / metabolism
Calcineurin Inhibitors*
Cyclosporine / pharmacology
Cyclosporine / therapeutic use
DNA-Binding Proteins / metabolism
Dermatitis, Atopic / metabolism*
Dermatitis, Atopic / pathology*
Dermatitis, Atopic / physiopathology
Forkhead Transcription Factors / metabolism
Humans
Intracellular Signaling Peptides and Proteins / metabolism
Mycophenolic Acid / analogs & derivatives
Mycophenolic Acid / pharmacology
Mycophenolic Acid / therapeutic use
Nuclear Proteins / metabolism
Purines / antagonists & inhibitors*
Purines / metabolism
Severity of Illness Index
T-Lymphocytes / drug effects
T-Lymphocytes / physiology*
Treatment Outcome
Tumor Necrosis Factor alpha-Induced Protein 3

Substances

Calcineurin Inhibitors
DNA-Binding Proteins
FOXP3 protein, human
Forkhead Transcription Factors
Intracellular Signaling Peptides and Proteins
Nuclear Proteins
Purines
Cyclosporine
Calcineurin
TNFAIP3 protein, human
Tumor Necrosis Factor alpha-Induced Protein 3
Mycophenolic Acid
purine